Skip to main content
OpenTrials
Completed

NCT Number: NCT01100112

(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets

Open-label, 8 week study, to assess the efficacy and safety of oral Budesonide-MMX 9 mg Extended-release Tablets in patients with mild to moderate, active ulcerative colitis who are not in remission based on the Ulcerative Colitis Disease Activity Index in study CB-01-02/01 (parent study [NCT00679432]).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colitis, Ulcerative Colitis Colonic Diseases Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Diseases Intestinal Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Santarus Clinical Investigational Site 9001, Andhra Pradesh, India

Loading trial locations.

About this study

Patients who complete the parent study and who do not achieve clinical remission will be eligible to receive 8 weeks of open-label treatment with Budesonide-MMX 9mg if they satisfy the entry criteria for this study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients 18 to 74 years of age, who are able to understand and voluntarily provide written informed consent
  • Completed all Final Visit assessments for study CB-01-02/01 (NCT00679432) and are not in clinical remission
  • Diagnosis of ulcerative colitis of mild to moderate severity with an Ulcerative Colitis Disease Activity Index (UCDAI) <or= 10 according to Sutherland
  • Females of child-bearing potential must have had a serum pregnancy test performed at the Final Visit of the parent study, and must use an acceptable contraceptive method throughout the treatment period. Female subjects must also not be actively breast-feeding through the entire study period.
  • Ability to comprehend the full nature and purpose of the study, including possible risks and side effects
  • Ability to co-operate with the investigator and to comply with the requirements of the entire study

Exclusion criteria

  • Did not complete study CB-01-02/01
  • Achieved clinical remission in study CB-01-02/01
  • Patients with severe ulcerative colitis (UCDAI >10)
  • Patients with infectious colitis
  • Evidence or history of toxic megacolon
  • Severe anemia, leucopenia, or granulocytopenia
  • Use of immunosuppressive agents in the last 8 weeks before the study
  • use of anti-tumor necrosis factor alpha agents in the last three months
  • Concomitant use of any rectal preparation for the treatment of ulcerative colitis
  • Concomitant use of antibiotics
  • Concurrent use of cytochrome P-450 3A4 (CYP3A4) inducers and CYP3A4 inhibitors.
  • Patients with verified, presumed of expected pregnancy or ongoing lactation
  • Patients with liver cirrhosis, or evident hepatic or renal disease or insufficiency and/or severe impairment of the bio-humoral parameters (i.e., 2x upper limit of normal for alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, or creatinine)
  • Patients with severe disease(s) in other organs of systems
  • Patients with local of systemic complications of other pathological states requiring a therapy with corticosteroids and/or immunosuppressive agents
  • Patients diagnosed with Type 1 diabetes
  • Patients diagnosed with or with a family history of glaucoma
  • Patients with known hepatitis B, hepatitis C, or with human immunodeficiency virus (HIV), according to the local privacy policy
  • Any other medical condition that in the principal investigator's opinion would make the administration of the study drug or study procedures hazardous to the subject or obscure the interpretation of adverse events

Treatment and study plan

Budesonide

Drug

One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.

Primary outcomes

  1. The Percentage of Patients Achieving Clinical Remission

    Time frame: At the end of the 8 week treatment period

    The primary efficacy endpoint is clinical remission at 8 weeks, defined as a Ulcerative Colitis Disease Activity Index score of < or = 1 with a score of 0 for both rectal bleeding and stool frequency, and > or = 1 point reduction from baseline in endoscopy score, without any sign of mucosal friability (a score of 0 for mucosal appearance).

    The UCDAI has 4 components. Each component is scored on scale of 0 to 3 (total maximum [worst] score = 12). Definitions of component scores are as follows: stool frequency: 0 = normal frequency, 1 = 1 - 2 stools per day greater than normal frequency, 2 = 3 - 4 stools per day greater than normal frequency, and 3 = > 4 stools per day greater than normal frequency; rectal bleeding: 0 = none, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood; physician's rating of disease activity: 0 = normal, 1 = mild, 2 = moderate, 3 = severe; mucosal appearance: 0 = normal, 1 = mild friability, 2 = moderate friability, 3 = exudation, spontaneous bleeding.

Secondary outcomes

  1. The Secondary Efficacy Endpoint is Clinical Improvement

    Time frame: After 8 weeks treatment period

    The secondary efficacy endpoint is clinical improvement, defined as a drop in the Ulcerative Colitis Disease Activity Index score of > or = 3 points from baseline.

  2. Safety Evaluations: the Numbers of Patients Who Experience Serious Adverse Events (SAEs) or Other Nonserious Adverse Events (AEs) During the Course of the Study.

    Time frame: Throughout the 8 week treatment period

    Safety will be assessed by evaluating SAEs and AEs. The outcome measure data are the numbers of patients who experienced SAEs or other nonserious AEs.

  3. Endoscopic Improvement

    Time frame: 8 weeks

    Greater or equal to a 1 point improvement in the mucosal appearance subscore of the ulcerative colitis disease activity index (UCDAI), from baseline to week 8.

    The UCDAI mucosal appearance subscore is graded as follows: 0 = normal, 1 = mild friability, 2 = moderate friability, 3 = exudation, spontaneous bleeding.

Sponsors and collaborators

Lead sponsor

Bausch Health Americas, Inc.

Industry

Collaborators

  • Cosmo Technologies Ltd

Registry information

Official study title

Multicenter, Open-Label Efficacy and Safety Study of Oral Budesonide-MMX 9mg Extended Release Tablets in Patients With Mild to Moderate, Active Ulcerative Colitis

Important dates

Study start
2010
Primary completion
2010
Study completion
2010
First posted
Apr 8, 2010
Registry last updated
Nov 29, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.